In Alzheimer's disease (AD), the brain's primary immune cells, microglia, become activated and are found in close apposition to amyloid beta (Aβ) protein plaques and neurofibrillary tangles (NFT). The present study evaluated microglia density and morphology in a large group of aged chimpanzees (n = 20, ages 37-62 years) with varying degrees of AD-like pathology. Using immunohistochemical and stereological techniques, we quantified the density of activated microglia and morphological variants (ramified, intermediate, and amoeboid) in postmortem chimpanzee brain samples from prefrontal cortex, middle temporal gyrus, and hippocampus, areas that show a high degree of AD pathology in humans.
| INTRODUCTION
Microglia are the primary immune cells in the brain and are widely dispersed across neocortical layers but show higher concentrations in the hippocampus (Graeber & Streit, 1990; Kongsui, Beynon, Johnson, & Walker, 2014; Lawson, Perry, Dri, & Gordon, 1990; Ransohoff & Perry, 2009 ). In the healthy brain, microglia use highly motile ramified processes to survey the cellular environment (Nimmerjahn, Kirchhoff, & Helmchen, 2005) . When infection, trauma, or neurodegeneration occur, microglia undergo rapid changes in cell morphology, gene expression, and function, a process known as microglial activation (Finsen, Lehrmann, Castellano, Kiefer, & Zimmer, 1996; Gehrmann et al., 1992; Jørgensen, 1993; Kofler et al., 2012; Lehrmann, Christensen, Zimmer, Diemer, & Finsen, 1997; Morioka, Kalehua, & Streit, 1992 , 1993 . Phenotypically, microglial activation results in a graded response of decreased arborization, enlarged cell soma, and shortened or total loss of cellular processes. Activated microglia also migrate to lesion or infection sites and can increase in density through mitotic proliferation to provide additional defense and restoration of tissue homeostasis (Kettenmann, Hanisch, Noda, & Verkhratsky, 2011) .
Microglia are macrophages implicated in the inflammatory response to the formation of amyloid beta protein (Aβ) plaques and neurofibrillary tangles (NFT) in Alzheimer's disease (AD) (Akiyama et al., 2000; Cunningham, 2013; Gandy & Heppner, 2013; Heneka, Kummer, & Latz, 2014; Hickman & El Khoury, 2014; Krstic & Knuesel, 2013; Perry & Holmes, 2014; Prokop, Miller, & Heppner, 2013; Sudduth, Schmitt, Nelson, & Wilcock, 2013) . It has been proposed that activated microglia stimulate neurons to overproduce Aβ, which results in the formation of extracellular plaques and hyperphosphorylation of the microtubule-stabilizing protein tau (Meraz Rios, ToralRios, Franco-Bocanegra, Villeda-Hernández, & Campos-Peña, 2013; Wyss-Coray & Rogers, 2012) . This process promotes increased microglial activation creating a positive feedback loop that plays a role in the pathological cascade that drives the development of AD.
In vitro work in human neuronal cell lines has demonstrated that inflammatory factors released from stimulated microglia upregulated mRNA and protein expression of all six tau isoforms and the production of amyloid precursor protein (APP), which is cleaved into Aβ peptides in AD (Lee, McGeer, & McGeer, 2015) . Activated microglia migrate towards Aβ plaques and NFT, participate in the clearance of Aβ, and proliferate at sites of Aβ deposition in the hippocampus (Cagnin et al., 2001; Hickman, Allison, & El Khoury, 2008; Higuchi, 2009; Maier et al., 2008; Maphis et al., 2015; Marlatt et al., shown colocalization of NFT, neuropil threads, and neuritic plaques displaying dystrophic (fragmented) microglial cells and an increase in microglia density in AD brains with high densities of NFT (Ekonomou et al., 2015; Streit, Braak, Xue, & Bechmann, 2009 ). Furthermore, the pharmacological inhibition of colony-stimulating factor 1 receptor, a necessary component for microglial signaling and survival, reduced 80% of total microglia and rescued dendritic loss, prevented neuronal loss, and improved contextual memory despite unaltered Aβ plaque loads (Spangenberg et al., 2016) .
Nonhuman primates also display microglial activation in response to Aβ deposits. Microinjection of insoluble fibrillary Aβ (fAβ) in the cerebral cortex of aged rhesus monkeys (Macaca mulatta) resulted in profound neuron loss, tau phosphorylation, and microglial proliferation (Geula et al., 1998) . Moreover, inhibition of microglial activation with a macrophage/microglia inhibitory factor eliminated fAβ toxicity in elderly macaque monkeys (Leung et al., 2011 ). Yet, until recently, evidence of the spontaneous co-occurrence of both Aβ and tau pathological markers of AD had not been found in species other than humans with the exception of a single aged chimpanzee and aged gorillas (Perez et al., 2013 (Perez et al., , 2013 Rosen et al., 2008) . Our recent work in aged chimpanzees (Pan troglodytes) demonstrated both Aβ and tau lesions, suggesting the pathologic hallmarks of AD are not limited to the human brain (Edler et al., 2017) . This study builds upon that foundation by evaluating activated microglia density and morphological changes of microglia in association with AD pathology in the same group of aged chimpanzees.
| MATERIALS AND METHODS

| Specimens and sample processing
Postmortem brain samples from 20 aged chimpanzees (Pan troglodytes; Table 1 ) were acquired from American Zoo and Aquariumaccredited zoos, American Association for Accreditation of Laboratory Animal Care-accredited research institutions, and the National Chimpanzee Brain Resource. All animals were maintained in accordance with each institution's animal care and use guidelines. Ninety-five percent of the founder chimpanzee population in the United States is Pan troglodytes verus, and all chimpanzees in this study were classified as this subspecies (Ely et al., 2005) . Chimpanzees in this study did not participate in formal behavioral or cognitive testing. Available health information for these apes was previously reported in supplemental table (S1) in Edler et al., 2017 . Sex and age was balanced as equally as possible. Samples from four brain regions, including prefrontal cortex (PFC, Brodmann's areas 9 and 10), middle temporal gyrus (MTG, Brodmann's area 21), and hippocampal subregions CA1 and CA3, were obtained from 8 male (ages 39-62 years) and 12 female (ages 37-58 years) chimpanzees.
Depending on availability, samples were taken from the right or left hemispheres. Brains were collected postmortem (postmortem interval < 20 h) and immersion fixed in 10% buffered formalin solution for at least 10 days. Specimens were transferred to a 0.1 M buffered saline solution containing 0.1% sodium azide at 4 C for storage prior to sectioning. Samples were cryoprotected in a graded series of 10, 20, and 30% sucrose solutions, and cut frozen into 40 μm-thick sections perpendicular to the main axis of the gyrus contained in each block using a Leica SM2000R freezing sliding microtome (Buffalo Grove, IL Nissl substance with a 0.5% cresyl violet solution to reveal cell somata and to define cytoarchitectural boundaries.
| Identification and regional sampling
All regions were identified using Nissl-stained sections. Brain areas and layers were selected based on NFT staging and Aβ deposition phases as reported in humans with AD and in aged chimpanzees (Braak & Braak, 1991; Edler et al., 2017; Gearing, Rebeck, Hyman, Tigges, & Mirra, 1994; Gearing, Tigges, Mori, & Mirra, 1996; Montine et al., 2012; Rosen et al., 2008) . Sampled regions included layer III in areas 9 and 10 of the dorsolateral PFC, layer III in area 21 of the MTG, and the stratum pyramidale in the hippocampal subfields CA1 and CA3. In AD, pyramidal layers III and V of the neocortex and stratum pyramidale in the CA1 field display extensive neuron and synapse loss, and the distribution of neuritic Aβ plaques and NFT is most prevalent in these cortical layers (Akram et al., 2008; Bussière et al., 2003; Hof, Cox, & Morrison, 1990; West, Coleman, Flood, & Troncoso, 1994 ). Pathology score refers to a pathology scoring system adapted from staging guidelines for Aβ and NFT deposition in AD and CAA with higher numbers corresponding to more severe pathology (Edler et al., 2017) . + positive for pathology, * does not follow staging pattern.
| Immunohistochemistry and antibody characterization
6E10 (Covance), Aβ42 (Invitrogen), AT8 (Goedert, Jakes, & Vanmechelen, 1995) , PHF-1 (Otvos et al., 1994) , and Iba1 (Wako).
Every 20th section was immunohistochemically processed using a rabbit anti-ionized calcium-binding adapter molecule 1 (Iba1) polyclonal antibody recognizing its C-terminus (1:10,000, Wako, 019-19741) following established protocols utilizing the avidin-biotinperoxidase method (Raghanti et al., 2008 (Raghanti et al., , 2009 . Iba1 is specifically expressed in macrophage/microglia and detects activated microglia.
Additional sections were double immunostained for Iba1 and tau, either using antibodies PHF-1 (1:10,000, Peter Davies) or AT8
(1:2,500, ThermoFisher, MN1020), to determine the co-localization of microglia and NFT. Free-floating sections were pretreated for antigen retrieval by incubation in 0.05% citraconic acid (pH 7. 
| Morphology identification
To measure potential phagocytic activity in microglia, we quantified densities for three activated morphological subtypes-ramified, intermediate, and amoeboid-as previously defined (Kettenmann et al., 2011) . Briefly, ramified morphology included long, highly arbor- 
| Data acquisition
Quantitative analyses were performed using computer-assisted stereology with an Olympus BX-51 photomicroscope equipped with a digital camera and StereoInvestigator software version 11 (MBF Bioscience, Williston, VT) by a single observer blinded to age and sex of study subjects. Initial subsampling techniques were performed for each probe to determine appropriate sampling parameters (Slomianka & West, 2005) . Densities for Iba1-immunoreactive 
| Statistical analyses
We previously collected data for APP/Aβ and Aβ42 plaque and vessel volume as well as AT8-ir pretangle, NFT, and tau neuritic cluster densities for each case included in the present study (Edler et al., 2017) . All densities and volumes were checked for linearity, and because skewness from means was close to zero, densities and volumes were transformed using the formula: arcsin [sqrt (density/1,000)]. To evaluate neuropathologic changes for each individual, a value was computed utilizing a pathology scoring system adapted from staging guidelines for Aβ and NFT deposition in AD and CAA (Edler et al., 2017) . Principal component analysis (PCA) was performed to reduce the number of pathological variables to the most relevant factors, and regression factors (PCA-generated brain pathology score) from this prior analysis were employed for further regression analyses with microglia densities in this study. Regression analyses were utilized to determine relationships between NC, HC, and total activated microglia density and morphological densities and ratios with chronological age, PCA-generated pathology score, sex, APP/Aβ and Aβ42 plaque and vessel volumes (%), and pretangle, NFT, and tau neuritic cluster densities (mm 3 ). Two-way ANOVAs with Bonferroni post hoc tests were used to examine sex and brain region differences in activated microglia and morphology densities. Statistical analyses were conducted using IBM SPSS Statistics, Version 22 (Armonk, NY). The level of significance (α) was set at 0.05. 
| Age and pathology correlations
Linear regression analyses did not reveal an association between chronological age and activated microglial density (p ≥ .45; Table 3 ). Densities of the different microglia morphologies, ratios of microglia subtype densities/activated microglia densities, and PHF-1/Iba1-ir microglia density also were not associated with chronological age (all p values ≥ .21; Table 3 ). The PCA-generated pathology score (Edler et al., 2017) , an assessment for overall Aβ and tau pathology in individuals, was not linked with activated microglia density, morphology, ratios, or PHF-1/Iba1-ir microglia density (all p values ≥ .08; Table 3 ). 
| DISCUSSION
Research examining neuroinflammation in nonhuman primates is scarce. Here, we present a quantitative study of activated microglia and morphological densities in association with AD-like lesions in aged chimpanzees.
Regional differences in activated microglia were noted in the hippocampus of aged chimpanzees with higher density in CA3 than CA1, including those apes displaying both Aβ and tau pathology (Figure 3) . A control group in a human AD study exhibited comparable, though nonsignificant, results with greater Iba1-ir microglia density in CA3 (160/ mm 2 ) than CA1 (115-120/mm 2 ) (Marlatt et al., 2014) . However, in the
Photomicrographs showing activated Iba1-ir microglia in the hippocampus of a 62-year old male chimpanzee (subject 20). Activated Iba1-ir microglia density (MGv, mm 3 ) was significantly higher in CA3 compared to CA1 in the hippocampus of aged chimpanzees (a; * represents a significant difference, p = .01). Sex differences were not observed in activated Iba1-ir microglia density (b; p = .68). Whiskers represent 1 SD. Small circles represent outliers (1.5 × interquartile range). Hippocampal subfield CA1 (c-e) has significantly decreased microglial activation than subfield CA3 (f-h). Stratum oriens (so), stratum pyramidale (sp), stratum radiatum (sr). Scale bars = 250 μm (c-d, f-g) or 25 μm (e,h)
FIGURE 4 Proportion of Iba1-ir activated microglia (MGv, mm 3 ) by morphology and region same study, the AD brains showed an increase in activated microglia density in CA1 but not CA3 compared to controls. In AD, the CA1 subfield of the hippocampus typically is one of the first areas affected by NFT and also associated with the greatest neuron loss, while CA3
remains relatively unaffected by tau lesions and neuron numbers are preserved (Braak & Braak, 1991; Mueller et al., 2010; Rössler, Zarski, Bohl, & Ohm, 2002) . Similar to humans, aged chimpanzees with AD-like pathology displayed higher pretangle, NFT, and tau neuritic cluster loads in CA1, although volume occupied by Aβ-positive plaques and blood vessels was greater in CA3 (Edler et al., 2017) . Additionally, Aβ42 immunoreactive plaque and vessel volumes were correlated with higher activated microglia densities in the hippocampus of these chimpanzees, indicating that increased microglial activation in CA3 compared to CA1 may be related to Aβ and not tau pathology (Miller et al., 1993) . This concept is supported by the lack of association of pretangle, NFT, and tau neuritic cluster densities with microglial activation in chimpanzees. In addition, a recent study of APP-overexpressing mice (hAPP-J20) demonstrated a correlation of greater total Aβ and microglial activation with neuronal loss in CA1, suggesting activation of microglia is closely associated with Aβ expression and neuron loss (Wright et al., 2013) . Taken together, these results demonstrate some important differences between humans and chimpanzees with AD pathology (Table 4) CA3, dentate gyrus, and amygdala (Marlatt et al., 2014; Schwarz, Sholar, & Bilbo, 2012) . In addition, young, middle-aged, and old female B6 mice had 25-40% more microglia in the dentate gyrus and CA1 than age-matched male C57BL/6J mice (Mouton et al., 2002) . Whether these regional or sex variances are species-specific requires further investigation of microglia in rodents, primates, and humans.
Among elderly chimpanzees, age was not associated with changes in activated microglia density or morphology. These data are congruent with previous findings in older nonhuman primates and rodents.
Activated microglia density in the visual cortex, substantia nigra, and ventral tegmental area of rhesus macaques did not show a significant increase with age (Kanaan, Kordower, & Collier, 2010; Peters & Sethares, 2004) . Similarly, changes in activated microglia density in the substantia nigra of young and middle-aged rats were not detected (Ogura, Ogawa, & Yoshida, 1994) . In contrast, aged rats demonstrated a mild-to-moderate increase in microglia activation in CA1 and CA3
hippocampal subfields (VanGuilder et al., 2011) . Moreover, some studies in humans demonstrate increased microglial activation, particularly in white matter tracts, with age (Morgan et al., 1999; Ogura et al., 1994; Perry & Gordon, 1991; Sheffield & Berman, 1998 ; Sloane, Jin G. Sheng, Mrak, & Griffin, 1997; Steiner et al., 2008; Tetreault et al., 2012) . Activated interleukin-1 alpha (IL-1α) microglia density is greater with age in humans (J G Sheng, Mrak, & Griffin, 1998) . IL-1α is a protein produced by activated macrophages and responsible for the production of inflammation. Additionally, age-related morphological changes in IL-1α microglia density were identified; intermediate and amoeboid morphologies, but not ramified, were more prevalent with age in humans independent of postmortem interval and sex (Sheng et al., 1998) . The number of amoeboid microglia was significantly increased in the human substantia nigra despite activated microglia densities not differing by age (Jyothi et al., 2015) . As the aim of the current study was to identify AD pathology-associated microglial activation, we collected data in the oldest available individuals, and therefore, it is likely that the present sample did not include individuals young enough to detect age-related differences in microglia densities.
Future examination of activated microglia density and morphology in young chimpanzees as well as young, middle-aged, and elderly humans is needed to address age-and species-related differences in microglial activation.
Similar to findings in humans, nonhuman primates, and rodent models of AD, aged chimpanzees exhibited greater levels of microglial activation and an increase in intermediate-shaped microglia morphologies associated with Aβ42 plaque and vessel volume in the hippo-
campus. Several studies demonstrate the presence of a robust Aβ pathology increases with age.
Aβ42 is the predominant peptide in severe CAA.
Aβ40 is the primary protein in humans with severe CAA.
Aβ pathology is associated with increased tau pathology.
Tau neuritic clusters lack an Aβ core.
Neuritic plaques contain an Aβ core.
Tau deposition occurs in microglia.
Pretangles in the neocortex increase with age.
NFT increase with age in the hippocampus.
NFT density is higher in hippocampal subfield CA1 compared to CA3.
Activated microglia density is higher in CA3 compared to CA1.
AD patients had higher microglial activation in CA1, despite control groups presenting with greater microglia density in the CA3.
Severe CAA is associated with increased tau pathology (NFT in humans; pretangles and tau neuritic clusters in chimpanzees).
Microglial activation is correlated with Aβ but not NFT lesions in the hippocampus.
Microglial activation is associated with Aβ and NFT pathology.
Aβ42 is correlated with increased microglial activation (plaques in humans, vessels in chimpanzees). Caudate nucleus 30,559/mm 3 NR = not reported; M = male; F = female; EC = entorhinal cortex; DG = dentate gyrus; DLPFC = dorsolateral prefrontal cortex; STG = superior temporal gyrus; ACC = anterior cingulate cortex; HC = hippocampus; FC = frontal cortex; TC = temporal cortex; PC = parietal cortex; OC = occipital cortex; AON = anterior olfactory nucleus; ITG = inferior temporal gyrus; PMC = premotor cortex; PV1 = primary visual cortex; IL-1α = interleukin one-alpha; HLA-DR = human leukocyte antigen-D related; CD45 = cluster of differentiation 45; Iba1 = ionized-binding calcium adapter 1; CD68 = cluster of differentiation 68.
CD33 (sialic acid binding Ig-like lectin 3), and HLA-DR (human leukocyte antigen-D related) in association with AD (Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013) . HLA-DR-ir microglia density was significantly higher in the MTG of AD patients than in controls, and CD33-ir microglia density was positively correlated with insoluble Aβ42 levels and plaque loads in AD brains (Carpenter et al., 1993; Griciuc et al., 2013) . Aβ oligomers also trigger astrocyte and microglial activation in mice and long-tailed macaque monkeys (FornyGermano et al., 2014; Ledo et al., 2013) . Additionally, evidence indicates cerebrovascular Aβ deposition promotes neuroinflammation in AD and cerebral amyloid angiopathy (CAA) disorders. In sporadic and familial CAA, leptomeningeal and cortical vessels were associated with an increased activation of monocyte/macrophage lineage cells (Yamada et al., 1996) . A transgenic mouse model (Tg-SwDI) of CAA showed abundant reactive astrocytes and activated microglia strongly associated with the cerebral microvascular fibrillar Aβ deposits (Miao et al., 2005) .
In addition to Aβ-positive plaques and vasculature, tau pathology correlates with neuroinflammation. Tau deposition was greatest in the intermediate microglial morphology as measured by PHF-1/ Iba1 immunoreactivity in aged chimpanzees (Figure 8a ). Furthermore, while tau lesions were not significantly associated with increased microglial activation, intermediate and amoeboid morphologies were noted adjacent to pretangles, NFT, and tau neuritic clusters (Figure 2i-l) . Microglial activation has been implicated in driving tau hyperphosphorylation, aggregation, and neurodegeneration in human models of tauopathies (Bellucci, Bugiani, Ghetti, & Spillantini, 2011; Gebicke-Haerter, 2001; Gerhard et al., 2006; Ishizawa & Dickson, 2001 ). Activated microglia are adjacent to tau-positive neurons in the brains of patients with progressive supranuclear palsy and corticobasal degeneration (Gerhard et al., 2006; Ishizawa & Dickson, 2001 ). Microglial activation also has been demonstrated to precede tau pathology in the P301S mouse model of tauopathy, and chemically or genetically enhanced microglial activation significantly accelerated tau pathology in the hTau mice (Bhaskar et al., 2010; Yoshiyama et al., 2007) . Recent work also showed that transfer of purified microglia derived from hTau mice induced tau hyperphosphorylation in the nontransgenic mouse brain, and inclusion of an IL-1 receptor antagonist significantly reduced microglia-induced tau pathology. These results suggest that reactive microglia may drive tau pathology in humans and rodents but not in chimpanzees (Maphis et al., 2015) . Rather, the combination of Aβ40 and Aβ42 is correlated to increased tau lesions in aged chimpanzees, whereas Aβ42 alone appears to activate microglia, potentially resulting in greater uptake of tau.
| Conclusions
Elderly chimpanzees exhibit changes in activated microglia density and morphology related to some AD pathologies, most notably in the hippocampus. The chimpanzee hippocampus, particularly the CA3 subfield, seems most susceptible to neuroinflammation with increased microglial activation as well as a greater number of microglia with intermediate morphology in relation to Aβ deposition but not tau lesions. This outcome diverges from humans with AD who display greater microglial activation and morphological changes in response to both tau and Aβ pathology, especially in the CA1 field. Such evidence supports prior work demonstrating the chimpanzee brain may be relatively preserved during normal aging processes compared to the human brain (Allen, Bruss, & Damasio, 2005; Bishop, Lu, & Yankner, 2010; Erwin, Nimchinsky, Gannon, Perl, & Hof, 2001; Erwin, Perl, Nimchinsky, & Hof, 1999; Finch, 2003; Jernigan et al., 2001; Sherwood et al., 2011) . Conversely, the chimpanzee brain may not be entirely protected from neurodegeneration as previously assumed and supported by the correlation of Aβ pathology and increased neuroinflammation in the hippocampus. Growing evidence suggests the detrimental cognitive effects of AD and other neurodegenerative diseases in humans may be the result of an increased lifespan and the further exaggeration of normal aging processes rather than evolutionary modifications in cerebral structure and function between chimpanzees and humans (Hof, Gilissen, & Sherwood, 2002; Rapoport & Nelson, 2011; Sherwood et al., 2011; Walker & Cork, 1999) . Future investigations will clarify the relationships by studying the effect of normal aging on microglia density and morphology as well as neuroinflammation in relation to potential α-synuclein pathology (e.g., Lewy bodies) in elderly chimpanzees.
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